Melatonin: Uses, Dosing, and Evidence

Melatonin is an endogenous hormone and widely used sleep supplement with a distinct evidence profile that differs substantially from conventional sleep medications. This page covers its physiological role, dose-response relationships, validated use cases, and the regulatory boundaries that define how it is classified and sold in the United States. Understanding where evidence supports melatonin use — and where it does not — matters because the supplement is available without a prescription yet carries real pharmacological effects on circadian rhythm and sleep.

Definition and scope

Melatonin (N-acetyl-5-methoxytryptamine) is a hormone secreted primarily by the pineal gland in response to darkness. Endogenous nighttime serum melatonin concentrations in healthy adults typically rise to between 80 and 120 picograms per milliliter (pg/mL), according to reference ranges cited by the National Institutes of Health (NIH MedlinePlus, Melatonin).

In the United States, exogenous melatonin is classified as a dietary supplement under the Dietary Supplement Health and Education Act of 1994 (DSHEA), regulated by the U.S. Food and Drug Administration (FDA) under 21 U.S.C. § 321(ff). This classification means manufacturers are not required to demonstrate efficacy or obtain pre-market approval before sale — a regulatory distinction that separates melatonin from prescription sleep aids reviewed under the FDA's New Drug Application pathway. The regulatory context for sleep-related products elaborates on how DSHEA shapes supplement labeling standards and permissible health claims.

Because melatonin is a supplement and not a scheduled drug, it is not subject to the Drug Enforcement Administration's controlled substance scheduling. However, the FDA retains authority to act against products making unauthorized disease claims or found to be unsafe.

How it works

Melatonin exerts its effects primarily through two G-protein-coupled receptors: MT1 and MT2, both expressed in the suprachiasmatic nucleus (SCN) — the brain's primary circadian pacemaker. Binding at MT1 receptors suppresses neuronal firing in the SCN, producing acute sleepiness. MT2 receptor signaling is more specifically associated with phase-shifting the circadian clock, which is the mechanism relevant to jet lag and shift-work applications.

The hormone does not function as a sedative in the pharmacological sense. It does not increase sleep duration through GABAergic pathways the way benzodiazepines or z-drugs do. Its primary action is chronobiotic — it signals to the body what time of day it is. This distinction is clinically significant: melatonin is more reliably effective at shifting sleep timing than at increasing total sleep in people whose circadian timing is already aligned.

Exogenous melatonin administered at low doses (0.5 mg) approximately 5 hours before habitual sleep onset can advance the circadian phase by roughly 1–1.5 hours, according to research summarized by the American Academy of Sleep Medicine (AASM Clinical Practice Guideline, 2015). Higher doses — commonly found in over-the-counter products, which frequently contain 5 mg to 10 mg — do not produce proportionally greater phase-shifting and may suppress endogenous melatonin production through receptor desensitization with prolonged use.

Common scenarios

Melatonin evidence varies considerably across use cases. The following structured breakdown reflects the primary clinical scenarios where it is studied:

  1. Jet lag: The strongest evidence base for melatonin involves transmeridian travel. Taking 0.5–5 mg at the target destination's bedtime for 2–4 days after eastward travel (which requires phase advancement) is supported by multiple randomized controlled trials. The Cochrane Collaboration reviewed 10 trials and concluded melatonin was effective for jet lag when taken at the correct phase (Cochrane Review: Melatonin for the prevention and treatment of jet lag, 2002).

  2. Shift work: Evidence is more modest. Melatonin can help shift workers sleep during daytime hours if timed correctly relative to individual shift schedules, but timing is difficult to standardize and compliance is variable.

  3. Delayed sleep-wake phase disorder (DSWPD): The AASM 2015 clinical practice guideline specifically recommends melatonin for DSWPD — a circadian rhythm sleep-wake disorder characterized by a persistent delay in the major sleep episode relative to social norms.

  4. Chronic insomnia in older adults: Endogenous melatonin production declines with age, and low-dose (0.5–2 mg) prolonged-release melatonin (sold in Europe as Circadin) has regulatory approval in the European Union for short-term insomnia treatment in adults aged 55 and older. In the U.S., no FDA-approved melatonin formulation exists for insomnia; the supplement pathway applies.

  5. Pediatric use: Melatonin is frequently used in children with neurodevelopmental conditions such as autism spectrum disorder and ADHD, where sleep-onset insomnia is common. The American Academy of Pediatrics has noted limited long-term safety data for pediatric populations, advising clinician involvement before sustained use.

Decision boundaries

Melatonin is not interchangeable with sleep medications. The evidence supports its use for circadian misalignment problems — jet lag, shift work, DSWPD — more robustly than for primary insomnia driven by hyperarousal, anxiety, or pain. Selecting melatonin for the wrong indication is a common misapplication.

Dose selection: Most effective circadian outcomes in research occur at 0.5–1 mg. Standard over-the-counter products in the U.S. typically contain 5–10 mg — doses 5 to 20 times higher than physiologically effective thresholds. The National Sleep Foundation references pharmacokinetic studies showing that 0.5 mg raises blood melatonin to roughly physiological nighttime levels, while 5 mg raises it to approximately 10 times normal (National Sleep Foundation, Melatonin and Sleep).

Timing dependency: The phase-shifting effect of melatonin is time-of-day dependent. Taking melatonin in the morning can phase-delay the clock; evening use phase-advances it. Incorrect timing can worsen the circadian disruption it is meant to address.

Contraindications and interactions: Melatonin can interact with anticoagulants (warfarin), immunosuppressants, and antidiabetic medications. The FDA's adverse event reporting database (FAERS) includes reports of pharmacodynamic interactions, though causality assessment varies.

Product variability: A 2017 study published in the Journal of Clinical Sleep Medicine found that melatonin content in 31 commercial supplements ranged from 83% below to 478% above labeled dose, with lot-to-lot variation of up to 465% within the same product (Erland & Saxena, JCSM 2017, DOI:10.5664/jcsm.6462). This variability is a direct consequence of DSHEA's pre-market framework.

For broader context on how sleep health information is organized and sourced, the home resource index provides orientation across topics.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)